As one of the latest advancements in genome editing, CRISPR-Cas9 has provided deep insights for geneticists and scientists who are … Keep Reading
[column width=”360px” padding=”20px”]We are in the midst of third quarter earnings reports, and they show with stark detail what the tsunami of patent losses means to the financial underpinning of drugmakers. It’s a serious problem that will erode earnings for years to come. Pharmaceutical researcher EvaluatePharma estimates there are $290 billion of sales at risk from patent expirations between this year and 2018.
[column width=”360px” padding=”20px”]The supercharged race to get new treatments into the lucrative market for treating rheumatoid arthritis (RA) appeared to thin considerably today as one contender dropped a study and another’s drug came up short against the existing competition.
Eskayef Bangladesh Limited, the world-class healthcare solution provider, is one of the leading and fastest growing pharmaceutical company of Bangladesh, which is engaged